Chemical Nameinfigratinib
Dosage FormCapsule (oral; 25 mg, 100 mg)
Drug ClassKinase inhibitors
CompanyQED Therapeutics
Approval Year2021


  • For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
Last updated on 5/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Truseltiq (infigratinib) Prescribing Information.2021QED Therapeutics Inc., Brisbane, CA